U.K. Government Relaxes Quarantine Rules For Travelers From 58 Countries

The U.K. government is relaxing quarantine rules for travelers arriving from 58 countries, who will no longer be required to self-isolate for 14 days when entering the country. Starting on July 10, travelers from a range of destinations including Spain, France, Italy and Germany will be able to move freely between countries. The UK Department…

U.K. Government Relaxes Quarantine Rules For Travelers From 58 Countries

The U.K. government is relaxing quarantine rules for travelers arriving from 58 countries, who will no longer be required to self-isolate for 14 days when entering the country.

Starting on July 10, travelers from a range of destinations including Spain, France, Italy and Germany will be able to move freely between countries. The UK Department for Transport says the named countries pose “a reduced risk to the public health of UK citizens.”

“Whether you are a holidaymaker ready to travel abroad or a business eager to open your doors again, this is good news for British people and great news for British businesses,” Grant Shapps, UK secretary of state for transport, said in a statement last week. “The entire nation has worked tirelessly to get to this stage, therefore safety must remain our watch word and we will not hesitate to move quickly to protect ourselves if infection rates rise in countries we are reconnecting with.”
All travelers will be required to provide the government with the address of where they will be staying on their trip. Some countries on the list, such as Spain, will require travelers to fill out a health questionnaire 48 hours ahead of travel.
Although the new rules apply to Wales and Northern Ireland, Scotland has issued its own, shorter list of countries that excludes Spain.
The UK has the third highest COVID-19 death toll in the world, with at least 44,687 people deaths and 289,165 cases.
Source : Time More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

The Company That Makes Remdesivir Says it Considerably Reduces COVID-19 Deaths

In a study, those getting remdesivir showed a 62% lower risk of mortality

The Company That Makes Remdesivir Says it Considerably Reduces COVID-19 Deaths
report published Friday, researchers from biopharmaceutical company Gilead Sciences said that COVID-19 patients receiving its antiviral drug remdesivir experienced lower mortality rates and better recovery times compared to those not getting the treatment.

The researchers compared 312 people hospitalized for COVID-19 and who received remdesivir to 818 people with similarly severe cases who were treated with standard of care, but did not need mechanical ventilation to breathe. Compared to the people in the latter group, those getting remdesivir showed a 62% lower risk of mortality during the study period. Furthermore, about 75% of patients receiving remdesivir recovered by day 14 after hospitalization, compared to 59% of those not getting the drug.

The findings were presented at the International AIDS Conference’s virtual COVID-19 conference, which Gilead is co-sponsoring.

The analysis did not follow the rigorous gold standard of comparing an experimental treatment group to a control group within the same study, a method that ensures the two groups are similar as possible and better accounts for potentially confounding factors. A previous remdesivir study that met such criteria, conducted by the National institute of Allergy and Infectious Diseases and reported in late April, showed that people taking remdesivir had a shorter recovery time. Given the urgency of finding a treatment during a quickly-worsening pandemic, the results prompted the NIH to decide that future studies of the drug (like those testing it in combination with other drugs, including anti-inflammatories) would not need a placebo group.

Gilead’s analysis is the next-best thing to a randomized placebo-controlled trial, and the company’s scientists acknowledge that more studies are needed to confirm the reduction in mortality. “To address the urgency of the continuing pandemic, we are sharing data with the research community as quickly as possible with the goal of providing transparent and timely updates on new developments with remdesivir,” Gilead Sciences Chief Medical Officer Merdad Parsey said in a statement.

Gilead also reported additional data showing that remdesivir provided similar benefit to people of racial and ethnic groups that seem to be more vulnerable to COVID-19 and its consequences. In another analysis of people who received the drug early in the pandemic (under the company’s compassionate use program), the scientists found that children and pregnant women taking the drug had similar benefits in improved oxygen measures.

Remdesivir is not yet approved by the Food and Drug Administration (FDA), but the agency issued an Emergency Use Authorization (EUA) for it on May 1, which allows doctors to request the drug for severely ill patients.

Source : Time More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.